TA-3 treatment significantly reduced phospho-Tau level in iPSC-derived neuronal cells from the AD patient (Figure 8A), suggesting that TA-3 might be able to reduce (phospho-)Tau level in human AD patients. Here, MAPT is linked to Alzheimer disease.